31846-36-3

Usage

Uses

Used in Pharmaceutical Industry:
7-HYDROXY-1,2,3,4-TETRAHYDRO-NAPHTHALENE-2-CARBOXYLIC ACID is used as a chemical intermediate for the development of drugs and medications. Its unique structure and properties make it a valuable component in the synthesis of new compounds with therapeutic properties.
Used in Research Applications:
7-HYDROXY-1,2,3,4-TETRAHYDRO-NAPHTHALENE-2-CARBOXYLIC ACID is used as a research compound for studying its potential anti-inflammatory and analgesic effects. Its chemical structure allows for investigation into its interactions with biological systems and its potential use in the development of new treatments for various conditions.
Used in Synthesis of New Compounds:
7-HYDROXY-1,2,3,4-TETRAHYDRO-NAPHTHALENE-2-CARBOXYLIC ACID is used as a building block in the synthesis of new compounds with potential therapeutic properties. Its versatile structure allows for the creation of novel molecules that may have beneficial effects in various medical applications.

InChI:InChI=1/C11H12O3/c12-10-4-3-7-1-2-8(11(13)14)5-9(7)6-10/h3-4,6,8,12H,1-2,5H2,(H,13,14)

Upstream product

• 24833-31-6 1,2,3,4-tetrahydro-7-methoxy-2-naphthalenecarboxylic acid 
• 6836-19-7 7-Methoxy-1-tetralone 
• 120072-87-9 methyl 1,2,3,4-tetrahydro-7-methoxy-1-oxo-2-naphthalenecarboxylate 
• 65844-56-6 methyl 1,2,3,4-tetrahydro-7-methoxy-2-naphthalenecarboxylate 

Downstream Products

• 1274816-84-0 4-([7-(([4-cyano-3-(trifluoromethyl)phenyl]amino)carbonyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)-N-methylpyridine-2-carboxamide 
• 1313494-65-3 4-([7-(([4-(aminomethyl)-3-(trifluoromethyl)phenyl]amino)carbonyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)-N-methylpyridine-2-carboxamide hydrochloride 
• 942072-08-4 ((R)-N-[3-(aminomethyl)-5-(trifluoromethyl)phenyl]-7-(2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalene-2-carboxamide 
• 942073-62-3 ((S)-N-[3-(aminomethyl)-5-(trifluoromethyl)phenyl]-7-(2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalene-2-carboxamide 
• 1355369-25-3 7-(3-chlorophenyl)-N-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxamide 
• 1355370-76-1 methyl 7-(3-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 1355371-41-3 methyl 7-(3-phenylureido)-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 1355371-31-1 methyl 7-{ [3-(1-methyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)benzoyl]amino}-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 1355371-27-5 methyl 7-(phenylsulfonamido)-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 1355371-26-4 methyl 7-(3-chlorophenylamino)-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 1355371-20-8 methyl 7-[3-(benzylamino)phenoxy]-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 1355371-15-1 methyl 7-{3-[(cyclopropylcarbonyl)amino]phenoxy}-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 1355371-10-6 methyl 7-(3-aminophenoxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylate hydrochloride 

Relevant academic research and scientific papers

Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors

Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY

The present invention provides novel bicyclic compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of va

Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives.

This invention encompasses compounds of Formula 1 and the pharmaceutically acceptable salts thereof. wherein R1 represents alkyl having 2-6 carbon atoms; R2 represents methyl or ethyl; R3 represents alkyl having 1 to 5 carbon atoms; W represents (CH?)x where x is 2 to 7, alkylene having 2 to 7 carbon atoms, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7 carbon atoms, or cyclopentyl; R? represents hydrogen, alkyl having 2-5 carbon atoms, alkenyl having 2 to 5 carbon atoms, or alkynyl having 2 to 5 carbon atoms; Q represents oxygen or CH?; B represents CH?, C=O or CH-OH; R? represents hydrogen, alkyl having 1 to 6 carbon atoms, or R? and R? together optionally represent a carbon to carbon bond; or R? represents alkanoyl having 2 to 4 carbon atoms, carboxy, alkoxycarbonyl, or (CH?)y-CO?R? wherein y is 0 to 4 and R? is hydrogen or alkyl having 1 to 6 carbon atoms; and A represents-Z-CO?R? or-Z-COR?R1? wherein R? represents hydrogen or alkyl having 1 to 6 carbon atoms, R?, R1?, represent hydrogen, alkyl having 1 to 6 carbon atoms, or cycloalkyl having 3 to 6 carbon atoms or NR?R1? form a heterocyclic ring, and wherein Z is absent or represents straight or branched chain alkylene or alkenylene having up to 6 carbon atoms.These compounds are selective antagonists of leukotriene B?(LTB?) with little or no antagonism of leukotriene D? (LTD?) and are useful anti-inflammatory agents for treating inflammatory bowel disease, rheumatoid arthritis, gout and psoriasis.

Di-and tetrahydronapthyl anti-allergy agents

This invention relates to compounds of the formula: and the pharmaceutically acceptable salts thereof:, wherein R1 represents straight or branched chain alkyl having 2-4 carbon atoms;, wherein R2 represents hydrogen or straight or branched chain alkyl having 1-6 carbon atoms;, wherein R3 represents hydrogen or straight or branched chain alkyl having 1-3 carbon atoms;, wherein R4 and R10 are different and represent H or n-propyl;, wherein X represents an interger from 2 to 5;, wherein R5 is hydrogen, or acts with R7 to produce an additional carbon--carbon bond between C1 and C2;, wherein R6 represents hydrogen or -Z-COOR9, wherein Z is either absent or represents straight or branched chain alkyl or alkenyl having 1-5 carbon atoms; and R9 represents hydrogen, pharmaceutically acceptable cations, or straight or branched chain alkyl having 1-6 carbon atoms;, wherein R7 is hydrogen, or acts together with R5 to form an additional carbon-carbon bond between C1 and C2, or acts together with R8 to form when R8 is oxygen;, wherein R8 is hydrogen, -O-R11, or oxygen, such that when R8 is oxygen, R8 acts together with R7 to form and, wherein R11 is straight or branched chain alkyl having 1-4 carbon atoms. The di- and tetrahydronaphthyl compounds of this invention are pharmacologically active as leukotriene D4 (LTD4) antagonists and are useful as anti--inflammatory and anti-allergy agents.

Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives

This invention encompasses compounds of Formula 1 and the pharmaceutically acceptable salts thereof. STR1 wherein R1 represents alkyl having 2-6 carbon atoms; R2 represents methyl or ethyl; R3 represents alkyl having 1 to 5 carbon atoms; W represents (CH2)x where x is 2 to 7, alkylene having 2 to 7 carbon atoms, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7 carbon atoms, or cyclopentyl; R4 represents hydrogen, alkyl having 2-5 carbon atoms, alkenyl having 2 to 5 carbon atoms, or alkynyl having 2 to 5 carbon atoms; Q represents oxygen or CH2 ; B represents CH2, C=O or CH--OH; R5 represents hydrogen, alkyl having 1 to 6 carbon atoms, or R5 and R6 together optionally represent a carbon to carbon bond; or R5 represents alkanoyl having 2 to 4 carbon atoms, carboxy, alkoxycarbonyl, or (CH2)y--CO2 R8 wherein y is 0 to 4 and R8 is hydrogen or alkyl having 1 to 6 carbon atoms; and A represents --Z--CO2 R7 or --Z--COR9 R10 wherein R7 represents hydrogen or alkyl having 1 to 6 carbon atoms, R9, R10, represent hydrogen, alkyl having 1 to 6 carbon atoms, or cycloalkyl having 3 to 6 carbon atoms or NR9 R10 form a heterocyclic ring, and wherein Z is absent or represents straight or branched chain alkylene or alkenylene having up to 6 carbon atoms. These compounds are selective antagonists of leukotriene B4 (LTB4) with little or no antagonism of leukotriene D4 (LTD4) and are useful anti-inflammatory agents for treating inflammatory bowel disease, rheumatoid arthritis, gout and psoriasis.